Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2016

View Archived Issues

Genentech initiates phase I trial of GDC-0134 in patients with ALS

Worldwide collaborations to control recent Zika virus outbreaks / News in Context

Researchers identify germline variants associated with melanoma prognosis

FDA approves Athenex's IND application for oradoxel

FDA accepts BLA submission for brodalumab in moderate to severe plaque psoriasis

Ixchelsis reports positive phase IIa results for IX-01 as treatment of premature ejaculation

Domainex and Cresset Discovery Services form alliance

Alkermes begins phase I clinical testing of ALKS-7119

FDA accepts for review cardiovascular outcomes data for Jardiance

Phase IIa study of GLPG-1205 in ulcerative colitis does not meet efficacy endpoints

Steba completes phase III trial of Tookad, submits MAA

Biomarkers linked to metastasis of endometrial and lung tumors

OncoMed unblinds phase II trial of tarextumab following DSMB analysis

Shire resubmits NDA for lifitegrast for dry eye disease

Results from part A of MoveDMD trial of CAT-1004 support progression to part B

WuXi Healthcare Ventures invests in Twist Bioscience and Syros Pharmaceuticals

Pharmaceutical industry calls for government collaboration to fight antibiotic resistance

Polish institutions report 5-HT/dopamine receptor modulators

Moberg Pharma issues a 5-year senior unsecured bond loan

Sunshine Lake Pharma discloses JAK3 inhibitors

Novartis reports soluble guanylate cyclase activators

Galapagos and Gilead Sciences file transparency notification

New animal model designed to reproduce ischemia in head and neck surgery

3D-printed biomimetic tympanic membrane shows similar acoustic properties to human eardrum

Tissue-engineered cartilage shows promise for laryngotracheal reconstruction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...